Vaccine Info

Measles Vaccines

Authored by
Last reviewed
September 6, 2023
Fact checked by
Robert Carlson, MD

Measles Vaccines 2023

Measles vaccination programs began in the United States in 1963 and will continue in 2023. The U.S. Centers for Disease Control and Prevention (CDC) published the measles vaccination schedules for children, adults, and international travelers visiting measles-outbreak areas in 2023, such as India. On August 17, 2023, the CDC is conducting a COCA webinar urging all healthcare providers to ensure their patients are up to date on the measles, mumps, and rubella (MMR vaccine). The CDC published Health Alert Network CDCHAN-00493 on June 21, 2023, with guidance for measles prevention for international travelers, and clinicians should be on alert for measles cases this summer.

The U.S. Food and Drug Administration (FDA) recently approved the intramuscular route of administration for M-M-R®II and ProQuad® vaccines on March 6, 2023. In addition, the FDA approved the Priorix vaccine to prevent measles, mumps, and rubella (MMR) in individuals one year and older. The U.S. CDC stated on November 18, 2022, that the Priorx and M-M-R II® vaccines are considered fully interchangeable, including for all off-label recommended uses. In addition, the CDC reported on January 13, 2023, nationally, 2-dose MMR coverage was 93.5% (range = 78% [Alaska] to 98% [New York]) during the 2020–21 school year. The CDC's Measles Clinical Presentation, Diagnosis, and Prevention Clinician Outreach and Communication Activity Call on  August 17, 2023, included these presentations.

The European Medicines Agency (EMA) endorses various measles vaccines, including, but not limited to, M-M-RVaxPro and Priorix; the U.K. offers MMR vaccines to babies and young children as part of the NHS vaccination schedule; and the World Health Organization (WHO) reported about 81% of children received one dose of measles vaccine by their first birthday in 2021, the lowest since 2008.

Measles Vaccines 2023

Merck & Co. M-M-R®II, a Measles, Mumps, and Rubella Virus Vaccine Live (M-M-R II) is approved by the U.S. FDA for use in people 12 months and older. And Proquad® is approved for children ages 1 through 12 who may also get the MMR and Varicella Virus vaccines. On August 1, 2023, Merck reported measles vaccine sales of $582 million were relatively flat compared with the prior year.

Priorix - Is licensed in the USA and over 100 countries for use in individuals aged 9 or 12 months, according to a 1- or 2-dose schedule, depending on the country. Priorix protects people against MMR. The CDC's MMR Vaccine Work Group presented: Overview of Measles by Ms. Lynn Bahta and Overview of GSK's Priorix MMR Vaccine by Remon Abu-Elyazeed, MD, Ph.D., U.S. Vaccines Medical and Clinical Affairs. 

Tresivac - This vaccine is available in India to prevent measles, mumps, and rubella. Serum Institute of India Ltd is the manufacturer.

Shanghai Institute of Biological Products released about 42 million MMR doses in China in 2020. 

Bio-MMR vaccine is offered in Brazil.

India MMR vaccine is offered to children.

MeasBio® (Biovac) in South Africa.

Indian Immunologicals Limited announced the approval from the Drugs Controller General of India for the manufacture of a Live Attenuated Measles-Rubella Vaccine.

Measles Vaccine Price

According to the U.S. CDC, measles vaccine prices range from $87.31 to $250.02 as of 2023. Additional measles vaccine prices and discount information are posted at InstantRx™.

Measles Outbreaks 2023

According to the CDC, the U.S. has maintained its measles-free elimination status for over twenty years. Measles outbreak news for 2023 is posted at this Vax-Before-Travel link.

Clinical Trials

No clinical trials found